drugset / Trial / NCT05505162

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162

Phase 1 Completed 24 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when administered alone and in combination with multiple oral doses of zibotentan.

Timeline

Start
2022-08-24
Primary completion
2023-01-10
Completion
2023-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule Oral
Subject Zibotentan Small molecule Oral
Subject ethinyl estradiol Small molecule Oral

Indications

No indication recorded.